High grade NMIBC BCG Naïve or no BCG within 2 years
Pfizer b8011006: Study of PF-06801591 in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-Risk Non-Muscle Invasive Bladder Cancer.
Phase: 3
Study Product: PF-06801591 in Combination With Bacillus Calmette-Guerin (BCG Induction With or Without BCG Maintenance) vs. BCG (Induction and Maintenance)
Estimated Study Completion Date: December 9, 2026
ClinicalTrials.gov Identifier: NCT04165317
High Grade NMIBC Post BCG
KEYNOTE-676: Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in HR NMIBC
Phase: 3
Study Product: Pembrolizumab with BCG
Estimated Study Completion Date: November 25, 2024
ClinicalTrials.gov Identifier: NCT03711032
KEYNOTE-057: Study of Pembrolizumab (MK-3475) in Participants With HR NMIBC
Phase: 2
Study Product: Pembrolizumab
Estimated Study Completion Date: July 30, 2023
ClinicalTrials.gov Identifier: NCT02625961
CheckMate 9UT: A Study of Nivolumab or Nivolumab Plus Experimental Medication BMS-986205 With or Without BCG in BCG Unresponsive Bladder Cancer That Has Not Invaded Into the Muscle Wall of the Bladder
Phase: 2
Study Product: Nivolumab vs. Nivolumab with BCG vs. Nivolumab with BMS-986205 vs. Nivolumab with BMS-986205 with BCG
Estimated Study Completion Date: April 16, 2023
ClinicalTrials.gov Identifier: NCT03519256
MIBC
Bladder Sparing
NanoDoce: Evaluation of NanoDoce in Subjects with Urothelial Carcinoma
Phase: 1/2
Study Product: NanoDoce Injection with NanoDoce Intravesical Instillation vs. NanoDoce Injection with Standard of Care
Estimated Study Completion Date: November 2020
ClinicalTrials.gov Identifier: NCT03636256
KEYNOTE-992: Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)
Phase: 3
Study Product: Pembrolizumab with Chemoradiotherapy (CRT) vs. CRT Alone
Estimated Study Completion Date: February 10, 2027
ClinicalTrials.gov Identifier: NCT04241185
Radical Cystectomy
KEYNOTE-905: Perioperative Pembrolizumab (MK-3475) Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer
Phase: 3
Study Product: Pembrolizumab with Radical Cystectomy plus Pelvic Lymph Node Dissection vs. Radical Cystectomy plus Pelvic Lymph Node Dissection
Estimated Study Completion Date: February 16, 2026
ClinicalTrials.gov Identifier: NCT03924895
Seattle Genetics EV-103: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
Phase: 1b/2
Study Product: neoadjuvant therapy followed by Radical Cystectomy for cis-ineligible MIBC – Cohort H: Enfortumab vedotin (EV), Cohort J: EV + Pembrolizumab
Estimated Study Completion Date: March 2026
ClinicalTrials.gov Identifier: NCT03288545
Locally Advanced or Metastatic UC
Seattle Genetics EV-103: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
Phase: 1b/2
Study Product: Cohort K: Enfortumab vedotin (EV) alone vs EV + Pembrolizumab for cis-ineligible patients
Estimated Study Completion Date: March 2026
ClinicalTrials.gov Identifier: NCT03288545
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember to talk to your healthcare providers first before making decisions about your plan of care.
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study. To learn more about our trials, call Jennifer at (843) 449-1010 ext. 316 or email us by filling out the form below.